Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Tetragenetics Announces Collaboration with Amgen

Published: Wednesday, April 03, 2013
Last Updated: Wednesday, April 03, 2013
Bookmark and Share
Exclusive research license of Tetragenetics’ technology for surface antigen drug target.

Tetragenetics Inc. a 2012 Gates Foundation Phase ll grant recipient and an emerging biotechnology company engaged in the development of particle-based vaccines and expression of membrane proteins for drug discovery, reported today that it has entered into a technology access and exclusive research license agreement with Amgen for a defined, but undisclosed, surface antigen.

Dr. Ted Clark, Founder and Chief Scientific Officer of Tetragenetics, said, “Tetragenetics has created a unique capability for making antigens which enable the discovery and production of novel antibodies that target validated but previously difficult to produce membrane protein drug targets.”

“One of the central problems that industry faces with an immunopharmacological approach to these intractable targets is presentation of the right extracellular domains. Tetragenetics’ discovery technology has distinct and quantifiable advantages over mammalian cells which, up until now, have been the principal cell lines available for discovery purposes,” continued Dr. Clark. “Our agreement with Amgen marks the second major partnership for Tetragenetics and the first for this specific family of targets.”

“Our collaboration with Amgen validates Tetragenetics’ proprietary drug discovery platform,” noted John Reilly, V.P. Business Development. “We will be announcing further collaborations with leading biotech and pharmaceutical companies as we expand our partnering programs.”

Tetragenetics’ technology enables high density heterologous expression of recombinant human membrane proteins on the cell surface of Tetrahymena thermophila. Immunogen preparations of the drug targets can be made in any of several formats: cell ghosts (“pellicles”), membrane vesicles, lipid rafts, or partially purified soluble protein. These enriched preparations are designed to enhance antibody production against the extracellular portions of the target.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Antarctic Sponge Extract Kills MRSA
New findings may provide opportunity for developing new drugs to fight dangerous bacteria currently highly resistant to treatment.
US-India Collab Finds Molecular Signatures of Severe Malaria
Study may be a significant advancement in understanding the causes of severe malaria.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!